Diane Le: From Biocatalytic Innovation to Process Development: Establishing an Ideal Manufacturing Route to Belzutifan

College of Science and Technology

An improved and sustainable synthesis of belzutifan (MK-6482), a novel oral first-in-class HIF-2 inhibitor, has been developed. The previous commercial process involved a lengthy 16-step sequence, including a cumbersome 5-step sequence to install a chiral benzylic alcohol by traditional methods. Key innovations in the new synthesis include the identification and directed evolution of FoPip4H, an iron/ -ketoglutarate-dependent hydroxylase enabling direct enantioselective C H hydroxylation of a simple indanone starting material, a base-metal-catalyzed sulfonylation, a KRED-catalyzed dynamic kinetic resolution, and a facile SNAr reaction conducted in water. Experimental and mechanistic studies of the SNAr step revealed product inhibition, which was rationalized. Together, these advances have shortened the synthesis to 9 steps and reduced the process mass intensity (PMI) by 75%, resulting in a greener, more efficient, and scalable manufacturing process for belzutifan.

OPEN TO: Undergraduate Students, Graduate Students, Faculty and Staff